Mandate

Vinge advises VEF Ltd in relation to the group’s change of domicile from Bermuda to Sweden

Vinge has advised VNV Ltd in connection with the process of changing the group’s domicile from Bermuda to Sweden (the “Redomestication”). The Redomestication is carried out by way of a scheme of arrangement under Bermuda law, whereby Swedish Depository Receipts in VEF Ltd are exchanged for shares in the Swedish group entity VEF AB (publ), which constitutes the new parent company of the group following the Redomestication. The shares of VEF AB (publ) is listed on Nasdaq First North Premier Growth Market.

VEF Ltd is an investment company that invests in growth stage private fintech companies. VEF focuses on scale emerging markets and invests across all areas of financial services inclusive of payments, credit, mobile money and wealth advisors.

Vinge’s team consisted of Jesper Schönbeck, Joel Wahlberg, Martin Boström and Anna Svensson (Capital Markets & Public M&A) and Maria Schultzberg (tax).

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025